On May 24, 2018 VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, reported that the Company will present an update on the OVAL Phase 3 trial of VB-111 in platinum-resistant ovarian cancer at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2018 Annual Meeting, to be held June 1-5 in Chicago, Illinois (Press release, VBL Therapeutics, MAY 24, 2018, View Source [SID1234526889]). In addition the Company will present data on its novel MOSPD2 program at the 2018 BIO International Convention, to be held June 4-7, 2018 in Boston.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
2018 ASCO (Free ASCO Whitepaper) Annual Meeting – Presentation Details
Title: Clinical trial in progress: A study of VB-111 combined with paclitaxel vs. paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).
Abstract: TPS5609
Session Title: Gynecologic Cancer
Date: June 4, 2018
Time: 1:15 PM-4:45 PM CDT
Location: Hall A
Poster Board: #331b
Presenter: Dr. Richard T. Penson, M.D.,MRCP, associate professor of Medicine, Harvard Medical School, clinical director of Medical Gynecologic Oncology, Massachusetts General Hospital
2018 BIO International Convention – Presentation Details
Date: Tuesday, June 5, 2018
Time: 2:45 pm EDT
Presentation Room: Theater 1
Location: Boston Convention & Exhibition Center
Webcast: Bio International Webcast Link
About VB-111 (ofranergene obadenovec)
VB-111, a potential first-in-class anticancer therapeutic candidate, is the Company’s lead oncology product currently being studied in a Phase 3 trial for ovarian cancer. VB-111 has received an Orphan Designation for the treatment of ovarian cancer by the European Medicines Agency (EMA). At the 2016 ASCO (Free ASCO Whitepaper), the Company presented data in platinum-resistant ovarian cancer, demonstrating a meaningful and significant increase in overall survival with VB-111 given in combination with chemotherapy (810 days vs. 172 days, p=0.042), along with a 60% durable CA-125 response rate—approximately two times the historical response observed with bevacizumab (Avastin) plus chemotherapy in ovarian cancer. The OVAL study is conducted in collaboration with the Gynecologic Oncology Group (GOG) Foundation, Inc., a leading organization for research excellence in the field of gynecologic malignancies.
About MOSPD2
MOSPD2 is a novel tumor-related target identified by VBL that may be used as a marker for selective targeting of several types of tumors. Research conducted by VBL has shown that MOSPD2 is a novel membrane protein found on tumor cells that is present when they start invading tissues or creating metastatic lesions. The Company believes that targeting of MOSPD2 may have several therapeutic applications, including inhibition of tumor cell metastases and targeting of MOSPD2-positive tumor cells. There are also potential applications in the inhibition of monocyte migration in chronic inflammatory conditions. VBL is developing the VB-600 series of pipeline candidates towards these applications.